MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.32
-0.01
-0.07%
After Hours: 14.30 -0.02 -0.12% 16:00 09/17 EDT
OPEN
14.18
PREV CLOSE
14.33
HIGH
14.51
LOW
14.06
VOLUME
355.26K
TURNOVER
--
52 WEEK HIGH
17.85
52 WEEK LOW
9.31
MARKET CAP
978.92M
P/E (TTM)
-10.4297
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DRNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

DRNA News

  • How Should Investors Feel About Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Pay?
  • Simply Wall St..1d ago
  • Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  • Business Wire.09/04 21:05
  • Dicerna to Present at H.C. Wainwright 21st Annual Global Investment Conference
  • Business Wire.09/03 21:05
  • 3 Biopharma Stocks With Over 50% Upside
  • TipRanks.09/03 08:20

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About DRNA

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
More

Webull offers Dicerna Pharmaceuticals Inc (DRNA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.